Comparison of Efficacy of Ivabradine Versus Metoprolol

NCT ID: NCT01755663

Last Updated: 2014-10-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ivabradine may be better than Metoprolol for controlling heart rate before Coronary CTA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ivabradine

Patients will recieved ivabradine(5) 1 tab bid pc for 3 day and the day of CT, and recieve placebo of metoprolol

Group Type EXPERIMENTAL

Ivabradine and Metoprolol

Intervention Type DRUG

metoprolol

Metoprolol (100) 1/2 tab bid pc for 3 day and the day of CT coronary , and placebo of ivabradine

Group Type ACTIVE_COMPARATOR

Ivabradine and Metoprolol

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ivabradine and Metoprolol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* elective patient on scheduled for 640 slices CT coronary at Phramonkutklao hospital
* Resting heart rate \> 70 BPM
* age \> 18 years and informed consent

Exclusion Criteria

* Heart rate \> 100 BPM
* BP \<100/60 mmHg
* recent congestive heart failure in 1 mo.
* SA node, AV node disease and AF
* on permanent pacemaker
* CrCL \< 15ml/min. , AST or ALT \> 3x UNL
* on HR reducing drug such as diltiazem, verapamil, digitalis
* contraindication for ivabradine or metoprolol
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Phramongkutklao College of Medicine and Hospital

OTHER

Sponsor Role collaborator

Col. Suthee Panichkul

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Col. Suthee Panichkul

Col. Suthee Panichkul

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Purich - Surunchupakorn, M.D.

Role: PRINCIPAL_INVESTIGATOR

Phramongkutklao College of Medicine and Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Phramonkutklao Hospital

Bangkok, , Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Purich Surunchupakorn, M.D.

Role: CONTACT

081-988-7390

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Purich Surunchupakorn, M.D.

Role: primary

081-988-7390

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pharmongkutklao

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.